Trigeminal Neuralgia - Pipeline Review, H1 2016

Published: Mar, 2016 | Pages: 55 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Trigeminal Neuralgia - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Trigeminal Neuralgia - Pipeline Review, H1 2016', provides an overview of the Trigeminal Neuralgia pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Trigeminal Neuralgia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Trigeminal Neuralgia and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Trigeminal Neuralgia
- The report reviews pipeline therapeutics for Trigeminal Neuralgia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Trigeminal Neuralgia therapeutics and enlists all their major and minor projects
- The report assesses Trigeminal Neuralgia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Trigeminal Neuralgia

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Trigeminal Neuralgia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Trigeminal Neuralgia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Trigeminal Neuralgia Overview 6
Therapeutics Development 7
Pipeline Products for Trigeminal Neuralgia - Overview 7
Trigeminal Neuralgia - Therapeutics under Development by Companies 8
Trigeminal Neuralgia - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Unknown Stage Products 11
Trigeminal Neuralgia - Products under Development by Companies 12
Trigeminal Neuralgia - Companies Involved in Therapeutics Development 13
Allergan Plc 13
Biogen, Inc. 14
Kineta, Inc. 15
Merz Pharma GmbH & Co. KgaA 16
Trigemina, Inc. 17
Trigeminal Neuralgia - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
(clonidine hydrochloride + naltrexone hydrochloride) - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
incobotulinumtoxin A - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
NeuroRelease TN - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
onabotulinumtoxin A - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
oxytocin - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
raxatrigine hydrochloride - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
U-2902 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Trigeminal Neuralgia - Recent Pipeline Updates 40
Trigeminal Neuralgia - Product Development Milestones 48
Featured News & Press Releases 48
Mar 03, 2016: PixarBio's Dr. Taunia Markvicka and Glenn Reiser to Discuss Breakthrough Data on Morphine Strength Non-Addictive Pain Treatment NeuroRelease at the 2016 Congress of Neurological Surgeons Spine Summit held in Orlando, FL March 17-18, 2016 48
Nov 30, 2015: PixarBio's Glenn Reiser to Present Data on NeuroRelease, a Breakthrough Non-opiate and Non-addictive Pain Platform, at the 2015 Life Sciences Summit in New York, NY 48
Oct 26, 2015: PixarBio Announces USFDA OPD Submission of NeuroRelease TN for Orphan Drug Designation for Trigeminal Neuralgia 49
Sep 23, 2014: Convergence Pharmaceuticals' Novel Nav1.7 Selective Sodium Channel Blocker CNV1014802 Demonstrates Proof of Concept in Second Neuropathic Pain Study in Lumbosacral Radiculopathy 49
Jun 16, 2014: Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-breaking Phase II Trigeminal Neuralgia Study 50
Jul 30, 2013: Convergence Pharmaceuticals Receives Orphan-Drug Designation for Nav1.7 Blocking Pain Drug CNV1014802 51
Apr 23, 2013: Convergence Pharma Announces Successful Interim Data From Phase II Trigeminal Neuralgia Study 51
Mar 27, 2013: Convergence Pharma Reports Positive Interim Data From Phase II Trigeminal Neuralgia Study Of CNV-1014802 52
Mar 19, 2012: Convergence Initiates Phase II Study For CNV1014802 For Trigeminal Neuralgia 52
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55

List of Tables

Number of Products under Development for Trigeminal Neuralgia, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Clinical Stage Development, H1 2016 9
Comparative Analysis by Early Stage Development, H1 2016 10
Comparative Analysis by Unknown Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
Trigeminal Neuralgia - Pipeline by Allergan Plc, H1 2016 13
Trigeminal Neuralgia - Pipeline by Biogen, Inc., H1 2016 14
Trigeminal Neuralgia - Pipeline by Kineta, Inc., H1 2016 15
Trigeminal Neuralgia - Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2016 16
Trigeminal Neuralgia - Pipeline by Trigemina, Inc., H1 2016 17
Assessment by Monotherapy Products, H1 2016 18
Assessment by Combination Products, H1 2016 19
Number of Products by Stage and Target, H1 2016 21
Number of Products by Stage and Mechanism of Action, H1 2016 23
Number of Products by Stage and Route of Administration, H1 2016 25
Number of Products by Stage and Molecule Type, H1 2016 27
Trigeminal Neuralgia Therapeutics - Recent Pipeline Updates, H1 2016 40